There is nothing specific about PAR management rather the market has marked down PR for creating repetitious milestone ambiguity.
When it comes to investing and in particular biotechs you have to embrace the process and most importantly be willingly to shoulder the inherent uncertainty and pain that comes with it.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-387
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $83.95M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.3¢ | $87.95K | 374.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 108273 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 49537 | 9 |
View Market Depth
| Last trade - 13.59pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.005 ( 2.17 %) |
||||
| Open | High | Low | Volume | ||
| 23.5¢ | 24.0¢ | 23.5¢ | 12651 | ||
| Last updated 14.14pm 14/06/2024 ? | |||||
| PAR (ASX) Chart |